Kornimate/medical-research-clean huggingface dataset:
cervical video assisted thoracoscopic surgery (c-vats)

Conditions: Lung Cancer

Summary: although thoracic notes may not be ready for human trials, a new minimally invasive technique to access the pleural cavity and perform pleural, pulmonary and mediastinal procedures would be possible. cervical video assisted thoracoscopic surgery (c-vats) is a technique that borrows from traditional vats procedures, from cervical mediastinoscopy, and from flexible endoscopy. all of these procedures are very familiar to the thoracic surgeon. the current feasibility and safety study examines c-vats as a method of evaluating, biopsying and performing pleurodesis in patients with pleural disease and or effusion.

hypothesis: c-vats is a feasible and safe method of entering the pleural space in order to perform pleural evaluation, pleural biopsy and pleurodesis in patients with pleural disease and/or pleural effusions. objectives: evaluate the safety and feasibility of c-vats in patients with pleural disease. design: prospective, cohort, feasibility and safety study. methods: patients referred to all thoracic surgeons in the division of thoracic surgery at the chum notre dame campus for the diagnosis or treatment of pleural based diseases will be screened for enrolment. the investigators plan to recruit 10 patients in this initial study. eligible patients will be consented by one of the thoracic surgeons at the chum. all procedures will be performing in the operating room at the chum notre dame hospital. all patients will be admitted prior to their procedure and treated on the post-operative thoracic surgery ward using standard post-vats procedural treatments. all cause, as well as procedure specific morbidity will be recorded by the study investigators on the day of the procedure, every day in hospital until discharge and at 1 week, 4 weeks and 12 weeks post procedure.

Eligibility criteria:
inclusion criteria: * eligible patients will be those that would be candidates for the same pleural procedure (biopsy, drainage and pleurodesis) using a vats technique exclusion criteria: * anticoagulation including warfarin, heparin or clopidogrel which cannot be stopped * patients less than 18 years old * pregnant patients * patient unable to extend neck fully * patients with cervical spine instability * patients having had previous neck or mediastinal surgery which would preclude mediastinoscopy * patients having previously undergone mediastinal irradiation * patients having been previously diagnosed with mediastinitis * active cervical cutaneous or deep cervical infections

Keywords: mediastinoscopy pleural evaluation pleural biopsy pleurodesis
chart review: drug utilization study in participants who received ozurdex™ (dexamethasone intravitreal implant) 0.7 mg injections for visual impairment due to diabetic macular edema (dme)

Conditions: Diabetic Macular Edema

Summary: a retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to dme treated with ozurdex implants in germany and switzerland from 1 january 2015 to 1 september 2017.


Eligibility criteria:
inclusion criteria: * participant received at least two ozurdex® implants in the study eye to treat visual impairment due to dme * first ozurdex® implant injection occurred after 1 january 2015 * participant was followed-up at the site for at least 12 months after the first ozurdex® implant in the study eye exclusion criteria: - participant received ozurdex® implants as part or during a clinical study
proactive outreach with fit

Conditions: Colorectal Cancer

Summary: the purpose of the study is to boost colorectal cancer (crc) screening rates in an underserved population in brooklyn through organized, proactive outreach of mailed fecal immunochemical tests (fit), utilizing evidence-based interventions tailored to the needs of the population.


Eligibility criteria:
inclusion criteria: patients * men and women aged 45-75 * receiving medical care at nyulh flatbush fhc and chn crown heights, east new york, east new york health hub, williamsburg clinic sites. * due or overdue for crc screening. * medical visit of any type at clinic in past year. providers * physicians or primary care givers at flatbush fhc or chn crown heights, east new york, east new york health hub, williamsburg clinic sites (chn employees) * provide care to crc screen-eligible patients exclusion criteria: * age younger than 45 years old or greater than 75 years old * up-to-date with colorectal cancer screening: * history of colorectal cancer, inflammatory bowel disease, colorectal polyps, or total colectomy * in hospice care * patients 66 years or older living long-term in an institution or with advanced illness * no address or phone number on file providers • no longer employed at an included clinic site
environment and lung cancer

Conditions: Cannabis Use

Summary: cannabis is the most consumed drug in the world and the french are the main consumers in europe. the most recognized effects of cannabis on human health are of a neuro-psychic nature. the medical literature on the effects of cannabis on the lung in general, and on lung carcinogenesis in particular, is most often reassuring (tashkin, chest 2018; zhang, int j cancer 2015; ghasemiesfe jama netw. open. 2019), despite the fact that the concentration of carcinogens in cannabis smoke is higher than that contained in tobacco smoke (moir, chem. res. toxicol. 2008), and that cannabis smoking has been implicated in the occurrence of ent cancers. rather, research focuses on the therapeutic effects of cannabis, especially analgesics, and even on its possible anti-tumor virtues (abrams, jama oncol. 2020). these reassuring data should, however, be viewed with a great deal of caution. on the one hand, the illegal nature of cannabis in most countries and its frequent association with tobacco consumption make studies on the subject difficult and often biased. on the other hand, the daily practice of oncologists, who observe numerous cases of advanced and rapidly progressive lung cancer occurring in young patients who are heavy users of cannabis, raises suspicion of an unrecognized role of cannabis in lung carcinogenesis. in a preliminary multicenter study on french patients under 50 years of age operated for primary lung cancer (betser, erj 2021), we demonstrated that cannabis consumption was extremely frequent, concerning 43% of patients, but mentioned in patients' medical records only in 4 out of 10 cases, while the smoking status was always noted. in addition, by comparing people who smoke cannabis (always here associated with tobacco) to patients who only smoke tobacco or to non-smokers, we identified a different profile of lung cancers, with more poorly differentiated tumors, presenting at a more advanced stage (more t3-t4 versus t1-t2) requiring more complex surgery, and mostly located in the upper lobes of the lung. similar research work is currently underway at gustave roussy (dr pradere-dr planchard, villejuif, france) on patients with metastatic lung cancer, with a focus on overall survival and molecular profile.


Eligibility criteria:
inclusion criteria: * any patient from 18 y.o to 59 y.o treated in one of the three above-mentioned hospitals for primary lung cancer, whatever its stage, and agreeing to participate in this research. exclusion criteria: * patient denied participation.

Keywords: cannabis, lung cancer
navigator vs standard needle injection for hip

Conditions: Hip Pain Etiology Unknown

Summary: the purpose of this randomized, parallel-group, single-blinded, single center, phase ii study is to collect data to compare the comfort and patient satisfaction of a hip injection delivered via the navigator compared to a standard needle injection. in addition, delivery preparation will be compared between a navigator injection and a standard hip injection. the data collected from this pilot study will serve as the basis to design a larger multi-center study.


Eligibility criteria:
inclusion criteria: * males and females, ≥18 years of age, of any race or ethnicity; * capable of completing self-administered questionnaires; * patients with suspected intra-articular hip pain who have failed conservative care (conservative care defined as a standard regimen of home or outpatient physical therapy, activity modification, trial of at least one nsaid) for at least 3 months; * candidate for a hip injection; * have been informed of the nature of the study, agreeing to its requirements, and have signed the informed consent approved by the institutional review board/ethics committee. * subjects are able to understand and speak english exclusion criteria: * history of intra-articular injection within the last 3 months prior to the injection procedure; * complex regional pain syndrome; * history of prior hip surgery; * history of substance abuse; * known history of hypersensitivity to local anesthetics of the amide type; * contraindicated for celestone (betamethasone sodium phosphate); * contraindicated for lidocaine hydrochloride; * is a prisoner or ward of the state; * are unable to meet the treatment and follow up protocol requirements.

Keywords: hip pain hip injection hip fracture hip bursitis hip arthritis hip sciatica
d2560c00015 flumist annual safety study 2018

Conditions: Influenza; Healthy

Summary: this prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in flumist quadrivalent for the 2018-2019 influenza season.

this prospective. randomized, double-blind. placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age (not yet reached their 50th birthday). eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of bivalent vaccine or placebo by intranasal spray. randomization will be stratified by site. this study will be conducted at 2 sites in the united states of america. each subject will receive 1 dose of investigational product on day 1. the duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.

Eligibility criteria:
inclusion criteria: * age 18 through 49 years * written informed consent * subject available by telephone * ability to understand and comply with the requirements of the protocol, as judged by the investigator exclusion criteria: * concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (day 181) * history of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations * any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example (eg\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renaldysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year * acute febrile (greater than \[\>\]100.0 degrees fahrenheit \[f\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days to randomization * any known immunosuppressive condition or immune deficiency diseases, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy * history of guillain-barre syndrome.

Keywords: bivalent. influenza. flumist quadrivalent. vaccine prevention in healthy adults.
effectiveness of kaltenborn end range joint mobilization technique and post facilitationstretch in shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: this study is a experimental one to observe the efficacy of joint mobilization and post facilitation techniques in shoulder impingement syndrome

his study is a experimental one to observe the efficacy of kalternborn end range joint mobilization and post facilitation techniques in shoulder impingement syndrome. goniometer, shoulder disability index will be the tool used for evaluation

Eligibility criteria:
inclusion criteria: * both male and female * age 25 to 45 * diagnosed rotator cuff impingement from ortho, neuro and musculoskeletal department * hawkin kennedy test positive * neer's test positive * jobe's test positive exclusion criteria: * cervical spine disorder * fractures * major upper limb surgery * tumor or wound * diagnosed acromial malformations
physiology and therapeutic management of neonatal abstinence syndrome

Conditions: Neonatal Abstinence Syndrome

Summary: the overall purpose of this project is to to quantify the physiology of neonatal drug withdrawal and develop non-pharmacological techniques to help improve the therapeutic management of neonatal abstinence syndrome (nas).

novel approaches to diagnosing and treating neonatal abstinence syndrome (nas) are needed for reducing prolonged pharmacological management, minimizing hospitalization and improving developmental outcomes in drug exposed newborns. this study seeks to examine the physiology and symptoms of drug withdrawal (e.g., irritability marked by movement activity; cardio-respiratory instabilities) in infants exposed to drugs in utero and test whether sensory stimuli (tactile, auditory) reduce dysregulated systems in the withdrawing infant. candidates at-risk for nas due to fetal drug exposure will be identified to investigators by the infant's primary medical caregiver. investigators will use a modified-consecutive sampling technique, restricted by equipment and personnel availability, for enrolling infants. participants will be studied throughout their hospitalization. effects of stimulation will be examined at different stages of withdrawal. efficacy of stimulation will be examined as a potential complementary treatment of nas.

Eligibility criteria:
inclusion criteria: eligible subjects are infants currently inpatient in the nicu or newborn nursery at university of massachusetts memorial hospital and: * full-term infants (\>37 wks gestational age) and late preterm infants (34-37 wks gestational age) * newborns at risk for nas due to fetal-drug exposure * at-risk infants will be infants who present with confirmed meconium and/or urine toxicology report (documented in medical chart review) for opioids (e.g., methadone, buprenorphine/subutex, oxycodone, heroin); may also have prenatal exposure to benzodiazepines, barbiturates, amphetamines, cannabinoids, alcohol, nicotine and/or caffeine. exclusion criteria: eligible infants meeting the inclusion criteria above will be excluded from participation in the study if he/she: * born less than \<34 weeks. * has a congenital abnormality * has a fetal anomaly * has hydrocephalus or intraventricular hemorrhage \>grade 2 * has a seizure disorder not related to drug withdrawal * has a clinically significant shunt * requires mechanical respiratory support

Keywords: stochastic resonance fetus/newborn infant drug withdrawal substance abuse
endothelial function in patients with sickle cell anemia before and after sildenafil

Conditions: Sickle Cell Anemia

Summary: the investigators would like to study the endothelial function in sickle cell patients without pulmonary hypertension in an in vivo method during a steady state condition before and after sildenafil treatment for 1 month, and to study the effects of this nitric oxide donor by measuring the flow mediated dilatation, by measuring endothelial progenitor stem cells colonies, and by measuring the effect of therapy on markers of inflammation (cell adhesion molecules and cytokines).


Eligibility criteria:
inclusion criteria: * patients with sickle cell anemia exclusion criteria: * patients with sickle cell anemia during acute crisis

Keywords: endothelial function endothelial progenitor stem cells
wal801cl (epinastine hydrochloride) dry syrup in paediatric perennial allergic rhinitis

Conditions: Rhinitis, Allergic, Perennial

Summary: study to investigate the efficacy of wal801cl dry syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of wal801cl dry syrup compared to ketotifen fumarate and to confirm the appropriateness of dosage of wal801 dry syrup.


Eligibility criteria:
inclusion criteria: * 15 years of age or younger * body weight of 14 kg or more * typical symptoms of perennial allergic rhinitis, and within 2 or higher score of serum specific immunoglobulin e (ige) caused by house dust (hd) or mite in the data obtained with the past one year * "moderate" or "severe" in the allergic rhinitis severity classification during the observation period * the patient diary can be entered by the patient or parent * outpatients exclusion criteria: * absolute necessity of treatment with a drug that may affect the evaluation of the effect of the investigational drug (e.g., anti-histamines, anti-allergics, steroid, vasopressors). patients being treated with the following drugs, however, may be included * intal® oral or inhalation * any eye drops other than zaditen® eye drop * external preparations (liniment, poultice) * initiation of desensitisation therapy within the past 6 months * onset of acute upper respiratory inflammation during the observation period * nasal disease, such as acute or chronic rhinitis, nasal polyp, hypertrophic rhinitis, septal deviation\*, sinusitis\*, and hypertrophied adenoid\*, of such a degree that the disease affects evaluation of the effect of the test drug (\*: x-ray examination will be conducted if necessary) * that pollen (cider, ragweed, japanese cypress, orchard grass, etc.) is a double antigen, and that the study will be conducted in the season of air-borne pollen, and symptoms may be exacerbated by pollen * present or past history of a convulsive disease, such as epilepsy (convulsion threshold values may be decreased by the comparator drug, ketotifen fumarate) * clinically significant abnormal changes in laboratory measurements, and thus judgement that the patient is ineligible for inclusion in this study; however, if the patient is judged as falling into grade 2 or more according to the mhw (ministry of health and welfare) adverse reaction severity classification criteria, the patient will be excluded from the study * clinically significant renal, hepatic or cardiac disease, or other complications, and thus judgement that the patient is ineligible for inclusion in the study; however, if the patient is judged as falling into grade 2 or more according to the mhw adverse reaction severity classification criteria, the patient will be excluded from the study * past history of drug allergy * 1 month, or 6 times as long as the half life of the investigational drug if it is over 1 month, will not have passed since participation in any other clinical trial study, at the time of the initiation of this study * judgement by the principal investigator or investigator that the patient is ineligible for inclusion in this study
effect of videogames on real-life triage patterns

Conditions: Trauma; Physician's Role

Summary: in 2016 and 2017 the investigators conducted two clinical trials in which emergency medicine physicians were randomized either to an intervention (customized, theoretically-based video games) or to a control (nothing or text-based education). this study will now assess long-term outcomes for physicians enrolled in those two trials to evaluate the effect of the interventions on triage practices for trauma patients who presented initially to non-trauma centers in the us between december 2016 and november 2018.


Eligibility criteria:
inclusion criteria: * participated in two prior clinical trials (physician) * ≥65 years old (patient) * enrolled in medicare fee-for-service * sustained a moderate-severe injury (i.e. iss \[injury severity score\] \>15) (patient) * treated by physician enrolled in prior clinical trials (patient) exclusion criteria: * did not participate in two prior clinical trials (physician) * \<65 years old (patient)
sleep and health outcomes in women with heavy menses

Conditions: Menstruation; Heavy

Summary: this study will evaluate subjective sleep over three consecutive menstrual cycles (menses and non-menses) in females reporting heavy menstrual bleeding. following a baseline phase of one menstrual cycle, study subjects will use a standardized nighttime feminine product during menstruation for their second cycle. for the third cycle, subjects will continue to use the standardized menstrual product with behavioral modification that includes refraining from those sleep behaviors used to avoid nighttime menstrual leakage.


Eligibility criteria:
inclusion criteria: * women aged 18-50 years old * generally healthy (self-assessed; no significant underlying disease) * premenopausal patients with regular menstrual cycles every 21 to 35 days * patients with at least 3 days and no more than 7 days of bleeding during menstruation * an intact uterus and at least one ovary * ability and willingness to provide written informed consent * willingness to adhere to study procedures * menstrual pads are the primary form for nighttime menstrual protection needs * will maintain a daily schedule that allows normal or typical sleep habits (ie, not a night-shift worker; \>5 hours of sleep). * women will self-report that they have heavy flow and perform at least one of the following compensatory behaviors: * set an alarm or plan to get up in the middle of the night to check or change the pad * add additional disposable absorbent products for extra leak protection of coverage (e.g. extra pads or liners) * use pillows or other means to limit sleep positions (to prevent moving at night) * use something extra on top of my bedding (such as a towel) to sleep on * wear an extra pair of pants/shorts * wear tighter clothing than they typically would, like yoga pants exclusion criteria: * currently pregnant or intending to imminently attempt pregnancy * any condition (social or medical) that, in the opinion of the primary care giver or study staff, would make trial participation unsafe or complicate data interpretation * difficult sleeping environment due to: * frequently involved in activities requiring nighttime awakenings (eg, taking care of an infant or loved one). * disruptive bed partners (i.e., snoring, children, pets, etc) * diagnosed sleep disorders (i.e. insomnia, sleep apnea, restless leg disorder, breathing disorder, etc) * use of an intrauterine device (iuds) unless copper iud. * regular use (\>1 day per week) of sleep aids and/or sedating medications, including over the counter products like melatonin.
revlimid® capsules special drug use-results survey (in patients with newly-diagnosed multiple myeloma [ndmm])

Conditions: Multiple Myeloma

Summary: to understand the safety and efficacy of revlimid® 2.5mg and 5 mg capsules (hereinafter referred to as revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. planned registration period this period started on the date of initial marketing of revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. planned surveillance period this period started on the date of initial marketing of revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.


Eligibility criteria:
inclusion criteria: * newly-diagnosed multiple myeloma who are treated with revlimid capsules exclusion criteria: * n/a

Keywords: second primary cancers cataracts newly-diagnosed multiple myeloma revlimid capsules